Daewoong Pharmaceutical’s Fexuclu gets green light in Indonesia

Daewoong Pharmaceutical said Friday that its self-developed gastroesophageal reflux disease, or GERD, drug Fexuclu has secured approval in Indonesia, marking a key step in its push into Southeast Asia’s fast-growing pharmaceutical market. The company said it plans to rapidly expand Fexuclu’s prescription base in Indonesia amid growing demand for more effective and convenient treatment options. According to the Korean drug maker, Fexuclu, a potassium-competitive acid blocker, or P-CAB, enables fa

By The Korea Herald